Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
相关临床试验
92
54 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
54
58.7%
已完成
19
20.6%
招募中
14
15.2%
终止
1
1.1%
撤回
4
4.3%
暂无批准数据
- Abivax reported positive topline results from the Phase 3 ABTECT-1 and ABTECT-2 induction trials of oral obefazimod in moderately to severely active ulcerative colitis. - The 50 mg once-daily dose produced a pooled placebo-adjusted clinical remission rate of 16.4% at Week 8, with 19.3% in ABTECT-1 and 13.4% in ABTECT-2. - No new safety signals emerged across either dose group, and Abivax plans NDA and MAA submissions in the second half of 2026 if the maintenance trial reads out positively.
- NetraMark Holdings Inc. has appointed Dr. Keith M. Fournier, PhD, RAC, a pharmaceutical executive with more than two decades of drug development and regulatory strategy experience, to its Board of Directors. - Dr. Fournier currently serves as Senior Vice President, Head of Regulatory Affairs at Abivax, and previously held senior leadership roles at AbbVie, EMD Serono (Merck KGaA), and MedImmune (AstraZeneca). - His experience includes leading cross-functional strategy for VENCLEXTA (venetoclax) programs and serving as Global Regulatory Lead for HUMIRA, spanning oncology, immunology, and autoimmune portfolios. - NetraMark's CEO George Achilleos stated that Dr. Fournier's regulatory and clinical development expertise will strengthen the Board as the company expands its NetraAI precision analytics platform across the pharmaceutical industry.
- Andera Partners, managing over $6 billion, uses a stage-diversified single-fund model spanning early-stage creation (20%), mid-stage Series B to phase one (50%), and late-stage public-market plays (30%). - Litzka argues biotech companies fail more often from "bad reasons" — operational, regulatory, and communication breakdowns — than from bad science, and boards must help companies "fail for the good reasons." - The Tupolis ADC pivot exemplifies the philosophy: the Munich company shifted from a weak clinical program to its versatile linker technology and was acquired by Gilead in 2026. - Litzka offers a measured view of AI as a productivity tool in patient preselection and compound selection, while warning that China's fast-moving ADC machinery poses a serious competitive threat.
- Abivax released Phase 3 topline data for obefazimod in ulcerative colitis showing strong efficacy outcomes but raising safety questions after several malignancy cases were reported. - The company's stock dropped 36.61% over seven days and 38.04% year-to-date following the clinical data release, erasing previous investor enthusiasm. - Despite the sharp decline, Abivax trades at a premium P/B ratio of 13.2x compared to the French biotech sector average of 4.2x, while reporting a net loss of €332.2 million. - A DCF valuation model suggests the stock may be trading 47.5% below its intrinsic value of €135.61, creating potential opportunity amid the clinical uncertainty.
- ACT Capital Management established a new $8 million position in TG Therapeutics, acquiring 268,875 shares despite the biotech's 30% stock decline over the past year. - TG Therapeutics' multiple sclerosis drug BRIUMVI generated approximately $606.9 million in product sales in 2025, nearly doubling year-over-year and driving total revenue to $616.3 million. - The company projects $875-900 million in total global revenue for 2026, driven by continued BRIUMVI adoption and international expansion efforts. - The investment represents 6.5% of ACT Capital's $123.67 million portfolio, positioning alongside other healthcare and biotech holdings including Krystal Biotech and Abivax.
- Revolution Medicines is reportedly in acquisition talks with Merck for up to $32 billion, which would represent the largest biotech deal since Pfizer's $45.6 billion acquisition of Seagen in 2023. - The potential acquisition comes as Merck faces patent expiry for its blockbuster cancer drug Keytruda in 2028, which generated $31.6 billion in sales last year and represents about half of the company's annual revenue. - Global biotech M&A activity has surged to $228.4 billion in announced deals in 2025, up from $132.3 billion in 2024, driven by pharmaceutical giants seeking to replace revenue from drugs losing patent protection. - Revolution Medicines' late-stage oral cancer treatment Daraxonrasib appears to be the key asset driving acquisition interest, with reports suggesting a potential bidding war occurred between multiple pharmaceutical companies.
- Abivax will present 22 scientific abstracts at ECCO 2026, including novel preclinical data showing obefazimod's first evidence of anti-fibrotic activity in inflammatory bowel disease models. - The oral presentation addresses intestinal fibrosis, a major complication in Crohn's disease that leads to strictures and often requires surgery, with no current efficacious anti-fibrotic treatments available. - Additional presentations will showcase subgroup analyses from Phase 3 ABTECT induction trials demonstrating obefazimod's clinical activity across diverse patient populations and favorable tolerability profile. - The comprehensive dataset includes efficacy, safety, and cytokine data showing downregulation of pro-inflammatory markers IL-17A and IL-6 in moderate-to-severely active ulcerative colitis patients.
- Eli Lilly is reportedly evaluating a potential acquisition of French biotechnology company Abivax, with representatives meeting French finance ministry officials in early December to discuss regulatory requirements. - The primary asset driving interest is obefazimod, Abivax's lead drug candidate that reported positive Phase 3 trial results in July 2025 for treating ulcerative colitis. - Abivax stock has surged over 1,500% in the past six months and gained approximately 16% following acquisition speculation reports. - The potential deal represents Eli Lilly's strategic diversification beyond its dominant GLP-1 obesity and diabetes franchise to establish stronger presence in immunology.
- Medicxi successfully raised €500 million ($581 million) for its sixth fund, demonstrating strong investor confidence in its asset-centric investment approach. - The fund will support biotechnology companies at all stages of drug development, focusing on single-asset companies with clear product visions to transform patient care. - Since its previous fund, Medicxi has created 16 new companies, achieved over 20 positive clinical data readouts, and realized more than $1 billion in returns across its portfolio. - The firm's total capital commitments now exceed €2 billion over the past decade, with notable portfolio successes including acquisitions of Merus, ProfoundBio, and ViceBio.
- Abivax shares soared over 850% following positive Phase III data in ulcerative colitis, creating an "Abivax effect" that has reshaped market dynamics and reignited investor confidence in European biotech. - The NEXT BIOTECH index climbed 13.7% year-to-date with most gains driven by a sharp rally since April's "Liberation Day," while companies trading below cash dropped from 20% to 16%. - Major pharmaceutical companies accelerated M&A activity in September, with Pfizer acquiring Metsera for up to $7.3 billion and Genmab acquiring Merus for $8 billion, confirming pharma's willingness to pay premium for late-stage assets. - Investors are now laser-focused on companies with pivotal readouts within 12 months, with Valneva's Lyme disease vaccine and Nanobiotix's head and neck cancer therapy emerging as key European watchlist names.
